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Objectives: The capacity of a human cell line to secrete recombinant factor VIII with a F309S
point mutation was investigated, as was the effect of the addition of chemical chaperones
(betaine and sodium-4-phenylbutyrate) on the secretion of factor VIII.
Methods: This work used a vector with a F309S mutation in the A1 domain to investigate FVIII
production in the HEK 293 human cell line. Factor VIII activity was measured by chromogenic
assay. Furthermore, the effects of chemical drugs on the culture were evaluated.
Results: The addition of the F309S mutation to a previously described FVIII variant increased
FVIII secretion by 4.5 fold. Moreover, the addition of betaine or sodium-4-phenylbutyrate
increased the secretion rate of FVIIIB proteins in HEK 293 cells, but the same effect was
not  seen for FVIIIB-F309S indicating that all the recombinant protein produced had been
efﬁciently secreted.
Conclusion: Bioengineering factor VIII expressed in human cells may lead to an efﬁcient
production of recombinant factor VIII and contribute toward low-cost coagulation factor
replacement therapy for hemophilia A. FVIII-F309S produced in human cells can be effective
in  vivo.
© 2016 Associac¸a˜o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published
by  Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license
Several studies have provided important information thatntroduction
emophilia A is an inherited disorder linked to the X
hromosome which results in deﬁciency or abnormality of
lood coagulation factor VIII (FVIII). The current therapy for
emophilia A patients is the intravenous infusion of plasma-
erived or recombinant factor VIII (rFVIII). The major problem
f replacement therapy with rFVIII is the low productivity
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which increases the cost of therapy. The high costs are
mostly attributable to several biochemical characteristics of
the recombinant protein such as the retention of FVIII within
the endoplasmic reticulum (ER) due to its interaction with dif-
ferent ER chaperones.1helped in the design and development of techniques to bio-
engineer rFVIII with better secretion efﬁciency.2,3 Swaroop4
developed an rFVIII with a point mutation in the A1 domain
 e Terapia Celular. Published by Elsevier Editora Ltda. This is an
mons.org/licenses/by-nc-nd/4.0/).
oter.136  rev bras hematol hem
(Phe309Ser) to increase secretion of the protein.4 However
despite many  signiﬁcant advances in the heterologous expres-
sion of FVIII, a low production rate persists.
Recently, it was suggested that recombinant concen-
trates might be associated with a higher incidence of
inhibitor development.5 This may be associated with the
different glycosylation pattern found in hamster cell lines
[available products are produced in Chinese hamster ovary
(CHO) and Baby hamster kidney (BHK) cells] compared to
human cells: Gal·1-3Gal1-(3) 4GlcNAc (-Gal) epitopes and N-
glycolylneuraminic acid (Neu5Gc) are not present in humans.6
As an alternative, human cell lines can be used to pro-
duce recombinant coagulation factors. This heterologous
expression system is capable of producing proteins with
post-translational modiﬁcations similar to their original coun-
terpart which might reduce the possibility of immunogenic
reactions.6
This study investigated the production of FVIII containing
the F309S point mutation in the HEK 293 human cell line and
the efﬁcacy of the molecule in vivo in a hemophilia A mouse
model.
Methods
Lentiviral  vectors
A human immunodeﬁciency virus-1 (HIV-1)-based lentiviral
vector containing the human FVIII cDNA with a deletion
of a large portion of the B domain (FVIIIB) and a sec-
ond vector with the Phe309Ser mutation (A1 domain) were
used to increase the secretion of the protein. The transgene
expression of both vectors was driven by the internal myelo-
proliferative sarcoma virus (MSV) promoter with selection
using the neomycin gene. The vectors were kindly provided
by Daniel Gibson from the Craig Venter Institute.
Transient  expression
FVIIIB and FVIIIB-F309S constructs were transfected (10 g
of DNA) into HEK 293 cells using lipofectamine® 2000 reagent
(Life Technologies) following the manufacturer’s instructions.
Conditioned medium was harvested at 48 h and 72 h after
transfection and analyzed using Asserachrom® VIII:Ag (Diag-
nostica Stago).
Production  of  lentiviral  particles
To generate lentiviral particles, the construct DNAs were tran-
siently introduced into 293FT cells by triple co-transfection
with the packaging construct pCMVR8.91 encoding gag,
pol, and rev and the pseudotyping construct pMD2.VSVG
coding for the vesicular stomatitis virus glycoprotein (VSV-
G). Transfection of plasmid DNAs was performed using
lipofectamine® (Life Technologies) following the manufac-
turer’s instructions. Viral particles were harvested at 48 h and
72 h post-transfection and ﬁltered through a 0.22 m ﬁlter
(Millex®-GV). The viral particles were concentrated by ultra-
centrifugation (1.40 h at 31,000 × g). The concentrated virus
was stored at −80 ◦C. 2 0 1 6;3  8(2):135–140
Lentiviral titers were determined by quantitative poly-
merase chain reaction (PCR) of genomic DNA from transduced
293FT cells. Brieﬂy, 1 × 105 293FT cells were seeded in a six-well
plate and transduced with serial dilutions of vector supple-
mented with 8 g/mL polybrene (Sigma-Aldrich). Genomic
DNA was extracted from transduced cells 72 h after transduc-
tion using the DNeasy Blood and Tissue Kit (Qiagen) as per the
manufacturer’s instructions, and quantitative PCR was car-
ried out in duplicate on samples to determine both total viral
DNA and human -actin levels (ACTB). The integrating copy
number per transduced cell was normalized assuming two
ACTB alleles per cell and infectious units per milliliter were
calculated as total viral DNA/(ACTB/2) × (1 × 105) × dilution
factor. Primers and probe used have been described
previously.7
Expression  of  stable  HEK  293  cells
HEK 293 cells were maintained in Dulbecco’s modiﬁed eagle
medium (DMEM – Life Technology) supplemented with 10%
(v/v) fetal bovine serum (Thermo Scientiﬁc), 1% (v/v) peni-
cillin/streptomycin solution (Gibco) in 5% CO2 at 37 ◦C. Cells
were plated onto 24-well plates (approximately 100,000 cells)
and transduced at a multiplicity of infection (MOI) of 40 for
transduction 1–4, MOI of 80 for transduction 5, and MOI  of
160 for transduction 6–10 with viral particles in a ﬁnal volume
of 500 L of DMEM supplemented with 8 g/mL of polybrene
(Sigma). At 24 h post-transduction, virus-containing media
was replaced with fresh DMEM and cells were allowed to
recover by culturing overnight at 37 ◦C in 5% CO2. Subse-
quently, transduced cells were replaced for another round
of transduction until the tenth cycle and analyzed for FVIII
activity, copy number integration, transcript expression and
protein analysis.
Factor  VIII  quantiﬁcation  and  antigen  analysis
FVIII activity was determined by a two-stage assay using the
COAMATIC FVIII (Chromogenix) according to the manufac-
turer’s instructions. Normal human reference plasma was
used to generate the standard curve. The FVIII antigen was
quantiﬁed by an enzyme-linked immunosorbent assay (ELISA)
method using the Asserachrom VIII:Ag (Stago) commercial Kit
according to the manufacturer’s instructions.
Reverse  transcription  polymerase  chain  reaction  analysis
RNA was extracted using the RNeasy Mini Kit (Qiagen) accord-
ing to the manufacturer’s instructions. Quantitative reverse
transcription-polymerase chain reaction (RT-PCR) was per-
formed using the High Capacity cDNA reverse transcription Kit
(Life Technology). This was followed by PCR with primers BiPfor
(5′-CCA ACG CCA AGC AAC CAA AG-3′), BiPrev(5′-CTT CTC CCC
CTC CCT CTT AT-3′), GAPDHfor (5′-GCC TCA AGA TCA TCA GCA
ATG C-3′), GAPDHrev (5′-CAT GGA CTG TGG TCA TGA GTC CT-
3′). SYBR Green real-time PCR was carried out using ABI Prism
7500 Sequence Detection System (Applied Biosystems) in a
total volume of 10 L containing 2.5 pM of each speciﬁc primer
and 2 L of cDNA. Gliceraldehyde-3-phosphate dehydroge-
nase (GAPDH) was used as endogenous control to standardize
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taining the F309S mutation secreted an average of ﬁve IU/10
cells/72 h of FVIII, that is, 4.5-fold more  efﬁciently than FVIIIB
as determined by two-stage clotting activity assay (Figure 2C).
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Figure 1 – Transient production of FVIIIB andrev bras hematol hemot
he amount of applied RNA. Relative immunoglobulin-binding
rotein (BiP) transcription levels were measured by applying
he 2−(Ct) equation.
estern  blot  analysis
onditioned medium was collected from transduced and non-
ransduced HEK 293 cells after 72 h and total protein was
uantiﬁed by the BCA Protein Assay Kit (Pierce). The cultured
ells were lysed in ice-cold lysis buffer containing protease
nhibitors (Complete mini-protease inhibitor cocktail, Roche)
nd centrifuged at 16,000 × g for 15 min. Total protein was
uantiﬁed by the BCA Protein Assay Kit (Pierce). Total pro-
ein (35 g and 40 g extracted from conditioned medium and
ysed cells, respectively) was separated by SDS-PAGE (4–20%
ini-PROTEAN, BIO-RAD), transferred to nitrocellulose mem-
ranes (40 m,  Hybond-C Extra, Amersham Bioscience) and
robed with anti-FVIII light chain mouse antibody (Santa
ruz Biotechnology) or anti-BiP/GRP78 mouse antibody (BD
ioscience). Internal control was achieved using anti -actin
ouse antibody (Sigma-Aldrich).
hemical  chaperone  treatment  of  transduced  cells
ransduced cells were seeded at a cell density of about
.5 × 106 cells per plate and were incubated in the presence
f chemical chaperones: betaine (Sigma-Aldrich) and sodium
-phenylbutyrate (Sigma-Aldrich) at different concentrations.
fter 72 h of incubation with chemical chaperones, levels of
ctive FVIII were determined in the supernatants. Experi-
ents were performed in duplicate.
n  vivo  assay
emophilia A mice (B6;129S4-F8tm1kaz/J) were obtained from
ackson Laboratory (Bar Harbor, ME,  USA). Adult mice, aged
–12 weeks, were used for tail clipping. All protocols were
onducted in accordance with the Ethical Code for Animal
xperimentation of the Council for International Organiza-
ions of Medical Sciences (CIOMS) and the Colégio Brasileiro de
xperimentac¸ão Animal (COBEA). This study was approved by
he Ethics Committee for Animal Research of the Universidade
e São Paulo (USP), Ribeirão Preto (#14.1.784.53.8).
evere  tail-bleeding  model
he tail-clip challenge was designed to analyze hemophilic
 mice after receiving one unit of culture supernatant
ontaining FVIIIB-F309S (n = 3 mice), FVIIIB (n = 3 mice)
r phosphate-buffered saline (PBS) (n = 3 mice). Mice were
nesthetized with 4.5% isoﬂurane and received culture super-
atant via retro orbital injection. After 10 min, bleeding was
nduced by cutting 1 cm of the tail and animal survival was
onitored over 50 h.tatistical  analysis
esults are expressed as means ± standard error of the mean
SEM) or standard deviation (SD) as appropriate. Student’s
npaired t-test and 95% conﬁdence interval were used for 1 6;3  8(2):135–140 137
comparisons between the groups. Two-way analysis of vari-
ance (ANOVA) was used to compare differences between the
indicated groups and the log-rank test was used to compare
the survival curves after the tail-clipping challenge. p-Values
<0.05 were considered statistically signiﬁcant.
Results
Transient  assay
In order to study the role of the F309S mutation on the secre-
tion and function of FVIII in human cell lines, a molecule with
this mutation was synthesized and cloned into a lentiviral vec-
tor. After, its secretion was analyzed by transient transfection
in HEK 293 cells. FVIII two-stage activity assays performed on
conditioned media harvested 48 h and 72 h after transfection
revealed that there was a better secretion of FVIIIB-F309S
over the FVIIIB levels (Figure 1).
The FVIIIB-F309S presented on average, 1.5 and 2 fold
higher secretion than FVIIIB in HEK 293 cells, after 48 h and
72 h of transfection. These results were reproducible and con-
sistent in three separate transfection experiments.
Generation  of  the  HEK  293  cell  line  stably  expressing
FVIIIB and  FVIIIB-F309S
To compare whether the mutation could also result in
increased secretion of FVIII in stable expression, HEK 293 cell
lines stably expressing FVIIIB and FVIIIB-F309S were gen-
erated. These cell lines were generated by lentiviral infection
followed by selection using geneticin. The number of lentivi-
ral vectors integrated into the genome were quantiﬁed for the
two generated strains (Figure 2A). The cell line FVIIIB-F309S
has one copy/cell of the lentiviral vector whereas the FVIIIB
has 1.4 copies/cell integrated in its genome.
The cell line containing the FVIII mutation expresses 9-
fold more  FVIII mRNA  than the cell with FVIIIB (Figure 2B).
The level of protein secreted in the cell with FVIIIB-F309S
is greater than the cell line with FVIIIB. The cell line con-
6FVIIIB-F309S in HEK 293 cells. The factor FVIII production
was measured by the enzyme-linked immunosorbent
assay (ELISA) technique. aStatistically signiﬁcant
differences between groups using Student’s unpaired t-test
(FVIIIB: p-value = 0.0042; FVIIIB-F309S: p-value = 0.0009).
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Figure 2 – (A) Number of lentiviral vectors integrated into
genome; (B) relative expression units (REU) of both
recombinant FVIII expressions and (C) Factor VIII
second-stage activity by a chromogenic assay (COAMATIC).
Data presented are the mean of three independent
experiments and the error bars represent the standard
deviation. Asterisks designate statically signiﬁcant
differences between groups using two-way ANOVA
Characterization  of  secreted  FVIIIB-F309S
FVIII protein has a 110-amino acid region within the A1-
domain that inhibits its secretion and contains multiple short
peptide sequences that have potential to bind to BiP. The
low level of FVIII secretion correlates with binding to the
BiP, within the lumen of the ER. To assess whether the high
expression of FVIII induces the production of BiP, the BIP
level was evaluated by Western blot. Figure 3 shows that FVIII
HEK293
BiP
Advate®
HC+LC
(without
processing)
HC+B
domain
deleted
HC+B
domain
β actin
Std
200 kDa
A
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FVIIIΔB
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FVIIIΔB-
F309S
FVIIIΔB-
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Figure 3 – Characterization of FVIII producing cell lines by
Western blot. (A) Cell lysates were  fractionated by
SDS–PAGE, and immunoblotted with BiP (78 kDa) and
b-actin (42 kDa) antibodies. (B) Supernatants of
non-transduced HEK 293 cells, 293 cells transduced with
FVIIIB and FVIIIB-F309S, and the control Advate®
immunoblotted with anti-heavy chain FVIII. 2 0 1 6;3  8(2):135–140
expression leads to an increased amount of BiP. However, there
are no signiﬁcant differences in BiP amounts between HEK 293
cells expressing FVIIIB and those expressing FVIIIB-F309S
(Figure 3A).
In order to characterize the secreted FVIIIr, Western blot
was performed with the anti-heavy chain monoclonal anti-
body. As expected, the HEK 293 cells expressing FVIIIB-F309S
secrete more  FVIII than HEK 293 cells expressing FVIIIB. It
was  possible to detect a 90 kDa band referring to the heavy
chain (Figure 3B).
However, it was not possible to identify clearly the band
referring to the heavy chain in the FVIIIB sample, prob-
ably because this cell produces a low amount of FVIII
thereby hindering antibody binding. In the band related to
the heavy chain, another band of ∼200 kDa was detected in
commercial FVIII corresponding to the heavy chain with B
domain (Advate®, Baxter). FVIIIB-F309S, which has the par-
tial deletion of B domain, also shows a band of ∼200 kDa,
suggesting that part of the FVIIIr released is composed
of heavy and light chains without intracellular cleavage
(Figure 3B).
The FVIIIB-F309S sample also showed fragments of
53 kDa and 43 kDa, which are probably related to the degra-
dation of FVIII. The 53 kDa band may correspond to part of the
A2 domain with the A1 domain (∼55 kDa) and the 43 kDa is
related to the A2 domain (Figure 3B).
Chemical  chaperone  supplementation  increases  the
secretion  of  FVIIIB  but  not  of  FVIIIB-F309S
In addition, two different compounds termed chemical chap-
erones (CC) were tested. These compounds are responsible
for non-speciﬁcally stabilizing native protein conformations
and supporting escape from the endoplasmic quality con-
trol system. Members of different compound classes of CC
(Betaine and sodium-4-phenylbutyrate) were tested for their
effect on FVIIIB and FVIIIB-F309S expression in HEK 293
cells. Betaine and sodium-4-phenylbutyrate were used at con-
centrations of 1 mM and 100 mM.  The drugs were tested
individually and in combination in the modiﬁed cell lines
expressing FVIIIB and FVIIIB-F309S.
The addition of betaine or sodium-4-phenylbutyrate
increased the secretion rate of FVIII-B proteins in HEK 293
cells (Figure 4). The combination of both drugs led to a further
increase in the secretion of FVIIIB. However, no increase in
the secretion of FVIIIB-F309S was observed with the addition
of betaine or sodium-4-phenylbutyrate or with the combina-
tion of these two compounds (Figure 4).
FVIIIB  and  FVIIIB-F309S  are  functionally  active  in
hemophilia  A  mice.
In order to investigate the FVIIIB and FVIIIB-F309S activity
proﬁle in vivo and whether they are able to stop bleeding in
hemophilia A mice, a dosage of 1 IU/mL of FVIIIB, FVIIIB-
F309S or PBS (as a negative control) was applied and then
tail bleeding was induced. Both FVIIIB and FVIIIB-F309S
groups were successful in stopping the bleeding. Furthermore,
all mice in the PBS group died within 50 h (Figure 5).
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Figure 4 – Effect of the betaine and
sodium-4-phenylbutyrate on FVIII secretion. HEK 293 cells
expressing FVIIIB or FVIIIB-F309S were incubated with
betaine and sodium-4-phenylbutyrate alone or in
combination. FVIII activity was determined in cell
supernatants after 72 h by chromogenic assay (n = 3).
aStatistically signiﬁcant differences between groups using
two-way ANOVA. p-Value = 0.0045. bStatistically signiﬁcant
differences between groups using two-way ANOVA.
p-Value = 0.0005.
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lipping. aStatistically signiﬁcant values (p-value = 0.0136).
iscussion
ecombinant FVIII protein is one of the most complex pro-
eins for industrial production due to the low efﬁciency of gene
ranscription, protein interactions with retention in the ER,
nappropriate transport from the ER to the Golgi apparatus and
he instability of the secreted protein.8–10 Over the years, other
esearch groups have studied ways to improve the expression,
ecretion and to increase the half-life of coagulation factors,
specially FVIII.2,11
In this study, the HEK 293 cell line was chosen due to the
arious advantages offered by this strain, for example, robust
attern of growth, easy maintenance, and high transfection
fﬁciency and production of proteins.12 The transient pro-
uction of rFVIII using the serum-free HEK 293 cell line in
uspension has been demonstrated yielding approximately
.64 IU/mL FVIIIr.13 More  recently, the pharmaceutical indus-
ry has developed the ﬁrst rFVIII produced in human cells
using the HEK293F strain) which showed efﬁciency in terms
f safety and production.14
The current study showed that the F309S mutation was able
o increase FVIII secretion by 3-fold compared to FVIIIB in 1 6;3  8(2):135–140 139
a stable HEK 293 cell line. This result is in accordance with
previous works.2,4 It is known that the inefﬁcient secretion of
FVIII is correlated with binding to the protein identiﬁed as BiP,
also known as the glucose-regulated protein 78 (GRP78) within
the lumen of the ER.15 Marquette et al. located a 110 amino
acid region within the A1 domain that inhibits FVIII secretion.
This region is clustered with multiple short peptide sequences
that have potential to bind to BiP.16 The results of Western
Blot in this study revealed that both FVIIIB-F309S and FVIIIB
increased BiP expression, although FVIII production was not
affected.
Another strategy used in this work to improve FVIII secre-
tion was to add chemical chaperones to culture cells. Betaine
is a chemical chaperone that can inhibit the aggregation of
FVIII and restore the intracellular trafﬁcking of loosely coiled
proteins. In addition to betaine, sodium butyrate, an organic
compound that has various effects on cell cultures, was also
tested; one effect is the induction of gene expression by his-
tone hyperacetylation promoting the activation of genes.17
This study shows that HEK 293 cells expressing FVIIIB
that had been treated with betaine and sodium butyrate
increased FVIII production. However, no effect was observed in
HEK 293 cells expressing FVIIIB-F309S treated with betaine.
Roth18 tested several chemical chaperones, including betaine
and reported that this compound increased the secretion
of FVIII because of the increased solubility of intracellular
FVIII aggregates and improved transport from the ER to the
Golgi apparatus.18 By contrast, the data of this study sug-
gest that all the FVIII produced by HEK 293 cells expressing
FVIIIB-F309S was secreted out of the cell and did not form
aggregates.
On the other hand, sodium butyrate increased FVIII pro-
duction in HEK 293 cells expressing FVIIIB either alone or
in combination with betaine. Previous studies have showed
that sodium butyrate produces a wide variety of effects on
cells in culture: arrest of cell growth, reversion of the trans-
formation characteristics of cells, and induction of proteins,
including enzymes, peptide hormones and hemoglobin.17
However, the same effect was not noticed in HEK 293 cells
expressing FVIIIB-F309S with the reason for this differ-
ence not being clear and thus further investigations are
needed.
Conclusion
The main contribution of this work is the production of a FVIII
molecule with a high secretion rate (with the F309S mutation
in the A1 domain), in order to increase the productivity and
decrease the production cost. Furthermore, this study utilized
a human cell line, HEK 293, to produce an rFVIII more  similar
to the existing FVIII in human plasma, and less immuno-
genic than the rFVIII commercially produced in hamsterConﬂicts  of  interest
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